-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Greenwich LifeSciences, Inc gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US3968791083 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 3.38 |
|---|---|
| PE Ratio | None |
| Target Price | 39 |
| Market Cap | 133M |
| Dividend Yield | None |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GLSI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
